Obsidian Therapeutics (OBX) SEC Filings, Aug 3, 2026

Obsidian Therapeutics, Inc. director Robert W. Ross reported his initial beneficial ownership, consisting solely of stock options over common stock. The reported positions include options exercisable at $0.71 per share for 180,000 underlying shares, fully vested and exercisable, and additional options exercisable at $0.78 per share for 175,000 and 162,500 underlying shares. The latter grant vests in sixteen equal quarterly installments following June 25, 2024, subject to his continued service.